Identification of small molecule inhibitors of pyruvate kinase M2

Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309 Kroemer, 2008, Tumor cell metabolism: cancer's Achilles’ heel, Cancer Cell, 13, 472, 10.1016/j.ccr.2008.05.005 Hsu, 2008, Cancer cell metabolism: warburg and beyond, Cell, 134, 703, 10.1016/j.cell.2008.08.021 Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809 Gatenby, 2004, Why do cancers have high aerobic glycolysis?, Nat Rev Cancer, 4, 891, 10.1038/nrc1478 Jones, 2009, Tumor suppressors and cell metabolism: a recipe for cancer growth, Genes Dev, 23, 537, 10.1101/gad.1756509 Christofk, 2008, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth, Nature, 452, 230, 10.1038/nature06734 Spoden, 2009, Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply, Exp Cell Res, 315, 2765, 10.1016/j.yexcr.2009.06.024 Jurica, 1998, The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate, Structure, 6, 195, 10.1016/S0969-2126(98)00021-5 Noguchi, 1987, The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters, J Biol Chem, 262, 14366, 10.1016/S0021-9258(18)47947-1 Noguchi, 1986, The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing, J Biol Chem, 261, 13807, 10.1016/S0021-9258(18)67091-7 Mazurek, 2005, Pyruvate kinase type M2 and its role in tumor growth and spreading, Semin Cancer Biol, 15, 300, 10.1016/j.semcancer.2005.04.009 Dombrauckas, 2005, Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis, Biochemistry, 44, 9417, 10.1021/bi0474923 Spoden, 2008, Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation, Int J Cancer, 123, 312, 10.1002/ijc.23512 Christofk, 2008, Pyruvate kinase M2 is a phosphotyrosine-binding protein, Nature, 452, 181, 10.1038/nature06667 Vander Heiden, 2001, Growth factors can influence cell growth and survival through effects on glucose metabolism, Mol Cell Biol, 21, 5899, 10.1128/MCB.21.17.5899-5912.2001 Yamada, 1999, Nutrient and hormonal regulation of pyruvate kinase gene expression, Biochem J, 337, 1, 10.1042/bj3370001 Mukohara, 2005, Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations, J Natl Cancer Inst, 97, 1185, 10.1093/jnci/dji238 Liu, 2001, Hypersensitization of tumor cells to glycolytic inhibitors, Biochemistry, 40, 5542, 10.1021/bi002426w Dwarkanath, 2001, Heterogeneity in 2-deoxy-d-glucose-induced modifications in energetics and radiation responses of human tumor cell lines, Int J Radiat Oncol Biol Phys, 50, 1051, 10.1016/S0360-3016(01)01534-6 Zhou, 2002, Genotoxic exposure is associated with alterations in glucose uptake and metabolism, Cancer Res, 62, 3515 Holdsworth, 2007, CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor, Am J Roentgenol, 189, W324, 10.2214/AJR.07.2496 Ben-Haim, 2009, 18F-FDG PET and PET/CT in the evaluation of cancer treatment response, J Nucl Med, 50, 88, 10.2967/jnumed.108.054205